Ipca Laboratories Limited Stock price Bombay S.E.

Equities

IPCALAB

INE571A01038

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:52 2024-03-28 am EDT 5-day change 1st Jan Change
1,238 INR +3.35% Intraday chart for Ipca Laboratories Limited +6.55% +11.22%
Sales 2024 * 75.72B 909M Sales 2025 * 89.16B 1.07B Capitalization 314B 3.77B
Net income 2024 * 6.28B 75.31M Net income 2025 * 9.55B 115M EV / Sales 2024 * 4.29 x
Net Debt 2024 * 10.66B 128M Net Debt 2025 * 4.51B 54.18M EV / Sales 2025 * 3.57 x
P/E ratio 2024 *
48.2 x
P/E ratio 2025 *
33 x
Employees 16,167
Yield 2024 *
0.37%
Yield 2025 *
0.46%
Free-Float 52.35%
More Fundamentals * Assessed data
Dynamic Chart
Ipca Laboratories Licenses Anti-Cancer Biosimilar Technology to Omexa Formulary MT
Nomura Adjusts IPCA Laboratories Price Target to INR1,308 From INR1,113, Keeps at Buy MT
Transcript : Ipca Laboratories Limited, Q3 2024 Earnings Call, Feb 15, 2024
Ipca Laboratories Limited Announces Appointment of Kamal Kishore Seth as the Lead Independent Director CI
Ipca Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Ipca Laboratories Limited, Q2 2024 Earnings Call, Nov 10, 2023
Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2023-24 CI
Ipca Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Ipca Laboratories' Pithampur Plant Classified as VAI by US FDA MT
Nomura Upgrades Ipca Laboratories to Buy From Neutral, Adjusts Price Target to INR1,133 From INR942 MT
INDIA STOCKS-Indian shares slide on Mideast jitters; ICICI Bank up on earnings beat RE
Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President ­ R&D (Formulations) CI
Ipca Laboratories Limited completed the acquisition of 19.29% stake in Unichem Laboratories Limited for INR 6 billion. CI
Ipca Laboratories' Piparia Manufacturing Plant in India Gets VAI Classification from US FDA MT
Nomura Adjusts IPCA Laboratories’ Price Target to INR942 From INR866, Keeps at Neutral MT
More news
1 day+3.35%
1 week+6.55%
Current month+3.87%
1 month+3.69%
3 months+16.98%
6 months+34.20%
Current year+11.22%
More quotes
1 week
1 174.00
Extreme 1174
1 245.00
1 month
1 121.25
Extreme 1121.25
1 245.00
Current year
1 058.70
Extreme 1058.7
1 264.00
1 year
670.00
Extreme 670
1 264.00
3 years
670.00
Extreme 670
1 383.55
5 years
422.10
Extreme 422.1
1 383.55
10 years
200.00
Extreme 200
1 383.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 80-04-01
Chief Executive Officer 51 03-04-15
Chairman 77 75-10-30
Members of the board TitleAgeSince
Chairman 77 75-10-30
Director/Board Member 76 11-08-15
Chief Executive Officer 51 03-04-15
More insiders
Date Price Change Volume
24-03-28 1,238 +3.35% 65 795
24-03-27 1,198 -0.25% 14,090
24-03-26 1,201 +0.31% 9,307
24-03-22 1,197 +2.06% 13,594
24-03-21 1,173 +0.95% 5,388

Delayed Quote Bombay S.E., March 28, 2024 at 06:00 am EDT

More quotes
Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
1,237 INR
Average target price
1,151 INR
Spread / Average Target
-6.97%
Consensus
  1. Stock
  2. Equities
  3. Stock Ipca Laboratories Limited
  4. Stock Ipca Laboratories Limited - Bombay S.E.